STORM Therapeutics
John Haurum has over 20 years’ experience in the international biotech industry. Previously John was Chief Executive Officer of F-star, a clinical-stage biopharmaceutical company pioneering the development of novel bispecific antibodies, with multiple strategic collaborations with AbbVie, Merck KGaA, Denali and Boehringer Ingelheim.
Prior to F-star, Dr Haurum was VP Research at ImClone Systems, and was previously CSO and Co-Founder of Symphogen. He is currently Executive Chairman of the Board at Synklino, Chairman of the Board of Agomab and is on the board of NeoPhore and Synact Pharma ApS. Dr Haurum has a Medical Degree and MSc in Immunology from Aarhus University, and a DPhil in Immunology from the University of Oxford.
This person is not in the org chart
This person is not in any offices
STORM Therapeutics
1 followers
STORM Therapeutics is a pioneer in the field of RNA epigenetics. We are an emerging biotechnology company in Cambridge, UK, focused on developing small molecule inhibitors of RNA-modifying enzymes for the treatment of cancer.